search
Back to results

Utilizing the HITSystem for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya (PARA)

Primary Purpose

Pediatric HIV Infection

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
HITSystem 3.0
Sponsored by
Global Health Innovations
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pediatric HIV Infection

Eligibility Criteria

1 Day - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Health facilities must meet the following criteria to be eligible for the trial:

  1. Level 3-5 and located in the Western Nyanza Province.
  2. Currently provide PMTCT, EID and paediatric ART programmes.
  3. Either government or private not-for-profit
  4. Agreement to participate, which will be granted by both Kisumu County minister of health, as well as the facility Director of Medical Operations (DMO).

Exclusion Criteria:

  1. Facilities that are classified as Level 1-2.
  2. Facilities that are participating in other research involving paediatric ART programmes.
  3. Private commercial facilities

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    HITSystem 3.0 Intervention

    Control

    Arm Description

    All HIV-positive children and their caregivers attending health facilities randomized to the HITSystem intervention arm will be monitored by the HITSystem. In the event that the child misses an appointment or a scheduled laboratory test, or the child's laboratory results suggest ART treatment failure, an automated SMS text message and alert will be generated in the HITSystem that will notify the child's health care provider. The child's caregiver will also receive a text message asking them to return to the clinic with the child. If the child is 16 years of age and considered an independent adolescent without a caregiver, the same process will be implemented, with the text messages being sent directly to the child. If the child's caregiver, or the independent adolescent, does not have a mobile phone, the health care provider will notify the community health worker (CHW) to trace the individual and visit them in their home.

    All HIV-positive children and their caregivers attending health facilities randomized to the Control arm will receive HIV/AIDS standard of care.

    Outcomes

    Primary Outcome Measures

    Pediatric ART Retention
    The proportion of HIV infected children in each arm who are retained in HIV care at 12 months. Retention will be defined as regular engagement with HIV care, as measured by having attended the last three scheduled monthly appointments on time.
    Pediatric Viral Load Suppression
    The proportion of HIV infected children who are virally suppressed (VL <50) at the end of the 12-month follow-up period.

    Secondary Outcome Measures

    Missed ART
    The proportion of HIV infected children who ever experienced a gap of >30 days without ART medication during the 12-month follow-up period.
    Medication Ratio >90%
    The proportion of HIV-infected children with an ART medication possession ratio of ≥90% during the 12-month follow-up period
    Viral Load Testing
    he proportion of HIV infected children who received viral load testing (per Kenya guidelines) at baseline, 6 months and 12 months

    Full Information

    First Posted
    June 4, 2019
    Last Updated
    June 6, 2019
    Sponsor
    Global Health Innovations
    Collaborators
    London School of Hygiene and Tropical Medicine, Kenya Medical Research Institute
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03980119
    Brief Title
    Utilizing the HITSystem for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya
    Acronym
    PARA
    Official Title
    Utilizing the HITSystem 3.0 for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2019
    Overall Recruitment Status
    Unknown status
    Study Start Date
    August 2019 (Anticipated)
    Primary Completion Date
    August 2021 (Anticipated)
    Study Completion Date
    December 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Global Health Innovations
    Collaborators
    London School of Hygiene and Tropical Medicine, Kenya Medical Research Institute

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Overall, there are an estimated 98,000 children living with HIV in Kenya. Children who are initiated on ART in Kenya and other low resource settings face several challenges with ongoing care due to current limitations of paediatric HIV treatment services. High quality paediatric HIV care requires routine monitoring of clinical and virologic status, support for ART adherence, and patient outreach to optimize retention in care. The HIV Infant Tracking System (HITSystem) is a web-based, system-level intervention that has dramatically improved EID HIV-related outcomes in Kenya, Tanzania, and Malawi. The objective of this study is to implement and evaluate the impact of HITSystem 3.0 on paediatric clinical outcomes, adherence, retention and viral suppression over 12 months among children in HIV care. Outcome measurements will be evaluated separately in children aged ≤2 years and in those aged 3-16 years. Primary Outcomes The proportion of HIV infected children in each arm who are retained in HIV care at 12 months. Retention will be defined as regular engagement with HIV care, as measured by having attended the last three scheduled monthly appointments on time (see section 3.3 for further description). The proportion of HIV infected children who are virally suppressed (VL <50) at the end of the 12-month follow-up period. The proposed trial design is an unblinded CRT with two arms: the HITSystem 3.0 Intervention vs. Standard of Care (SOC) as the control. The CRT will be implemented in 20 health facilities (10 intervention and 10 control) in Western Nyanza province in Kenya and will collect data from HIV-infected children aged ≤16 years. Outcomes will focus on ART retention, adherence and viral suppression. Outcomes will be assessed among all HIV positive children aged ≤16 years attending the trial facilities for HIV care at the start of the trial, or who are diagnosed as HIV positive during the first 12 months of the trial. Follow-up data will be collected on each child for 12 months. Therefore, the total duration of the trial will be for 24 months. All HIV-positive children and their caregivers attending health facilities randomised to the intervention arm will be monitored by the HITSystem 3.0. The study will be conducted in Western Nyanza province, Kenya, which comprises six counties.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pediatric HIV Infection

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    1160 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    HITSystem 3.0 Intervention
    Arm Type
    Experimental
    Arm Description
    All HIV-positive children and their caregivers attending health facilities randomized to the HITSystem intervention arm will be monitored by the HITSystem. In the event that the child misses an appointment or a scheduled laboratory test, or the child's laboratory results suggest ART treatment failure, an automated SMS text message and alert will be generated in the HITSystem that will notify the child's health care provider. The child's caregiver will also receive a text message asking them to return to the clinic with the child. If the child is 16 years of age and considered an independent adolescent without a caregiver, the same process will be implemented, with the text messages being sent directly to the child. If the child's caregiver, or the independent adolescent, does not have a mobile phone, the health care provider will notify the community health worker (CHW) to trace the individual and visit them in their home.
    Arm Title
    Control
    Arm Type
    No Intervention
    Arm Description
    All HIV-positive children and their caregivers attending health facilities randomized to the Control arm will receive HIV/AIDS standard of care.
    Intervention Type
    Other
    Intervention Name(s)
    HITSystem 3.0
    Intervention Description
    The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
    Primary Outcome Measure Information:
    Title
    Pediatric ART Retention
    Description
    The proportion of HIV infected children in each arm who are retained in HIV care at 12 months. Retention will be defined as regular engagement with HIV care, as measured by having attended the last three scheduled monthly appointments on time.
    Time Frame
    12 months
    Title
    Pediatric Viral Load Suppression
    Description
    The proportion of HIV infected children who are virally suppressed (VL <50) at the end of the 12-month follow-up period.
    Time Frame
    12 months
    Secondary Outcome Measure Information:
    Title
    Missed ART
    Description
    The proportion of HIV infected children who ever experienced a gap of >30 days without ART medication during the 12-month follow-up period.
    Time Frame
    12 months
    Title
    Medication Ratio >90%
    Description
    The proportion of HIV-infected children with an ART medication possession ratio of ≥90% during the 12-month follow-up period
    Time Frame
    12 months
    Title
    Viral Load Testing
    Description
    he proportion of HIV infected children who received viral load testing (per Kenya guidelines) at baseline, 6 months and 12 months
    Time Frame
    Baseline, 6 months, 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Day
    Maximum Age & Unit of Time
    16 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Health facilities must meet the following criteria to be eligible for the trial: Level 3-5 and located in the Western Nyanza Province. Currently provide PMTCT, EID and paediatric ART programmes. Either government or private not-for-profit Agreement to participate, which will be granted by both Kisumu County minister of health, as well as the facility Director of Medical Operations (DMO). Exclusion Criteria: Facilities that are classified as Level 1-2. Facilities that are participating in other research involving paediatric ART programmes. Private commercial facilities
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Brad Gautney, MPH
    Phone
    913-706-3120
    Email
    brad.gautney@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    May Maloba, RN
    Phone
    +254 720 254069
    Email
    maymcurtis@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Brad Gautney, MPH
    Organizational Affiliation
    London School of Hygiene and Tropical Medicine
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    All collected IPD, all IPD that underlie results in a publication)
    IPD Sharing Time Frame
    Data will become available upon publication of results.
    IPD Sharing Access Criteria
    Only PI, appropriate research members and publication editor will have access.

    Learn more about this trial

    Utilizing the HITSystem for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya

    We'll reach out to this number within 24 hrs